Cited by 584Psychedelics and Drug StudiesSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, Teri S, Johansen, Pål-Ørjan·2012·Journal of Psychopharmacology

DOI 10.1177/0269881112439253

Open this paper in CoChat — free account

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36–2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I 2 = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Integrity signals

Registry

Crossref · 10.1177/0269881112439253

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Untitled work
(2008) · Cited by 3,790
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 762
Alcohol-use disorders
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455

Show all 39 references

Research works printed but not linked: 6

Ables MF, 1967, Highlights of the twelfth annual conference in cooperative studies in psychiatry
Ables MF, 1970, Group treatment of chronic alcoholism with LSD-25: study II. Newsletter for research in psychology, United States Veterans Administration, 12, 17
American Psychiatric Association (1952) Diagnostic and Statistical Manual for Mental Disorders. First Edition. Washington, DC: American Psychiatric Association, 39.
Kurland AA, 1971, Advances in neuropsychopharmacology: proceedings of the 7th congress of the collegium internationale neuro-psychopharmacologicum, 361
Rösner S, 2010, Cochrane Database Syst Rev, 9, CD004332
Rösner S, 2010, Cochrane Database Syst Rev, 12, CD001867

Sorted by citations

Items 101–200 of 584

Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
Why was early therapeutic research on psychedelic drugs abandoned?
Hall, W. (2021) · Psychological Medicine · doi:10.1017/s0033291721004207 · Cited by 98
Therapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 92
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users
Morgan, C. J. A., Noronha, L. A., Muetzelfeldt, M., Feilding, A., & Curran, H. V. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113477744 · Cited by 92
Repeated low doses of LSD in healthy adults: A placebo‐controlled, dose–response study
de Wit, H., Molla, H. M., Bershad, A. K., Bremmer, M. P., & Lee, R. (2022) · Addiction Biology · doi:10.1111/adb.13143 · Cited by 85
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., Wallach, J. V., & Halberstadt, A. L. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1884 · Cited by 81
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., Scherbaum, N., & Klein, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05477-0 · Cited by 76
Research abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss, D., de la Salle, S., Sloshower, J., & Williams, M. T. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107262 · Cited by 75
Associations between lifetime classic psychedelic use and markers of physical health
Simonsson, O., Sexton, J. D., & Hendricks, P. S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121996863 · Cited by 74
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Divito, A. J., & Leger, R. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06009-x · Cited by 78
Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders
Oehen, P., & Gasser, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863552 · Cited by 73
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 70
Psychedelic Psychotherapy: Insights From 25 Years of Research
Richards, W. A. (2016) · Journal of Humanistic Psychology · doi:10.1177/0022167816670996 · Cited by 83
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder
Zeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
Untitled work
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research
Nutt, D. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002047 · Cited by 67
The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens
Canal, C. E., & Murnane, K. S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677104 · Cited by 73
The epistemic innocence of psychedelic states
Letheby, C. (2016) · Consciousness and Cognition · doi:10.1016/j.concog.2015.11.012 · Cited by 67
Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy
Walsh, Z., & Thiessen, M. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474088 · Cited by 58
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0694-z · Cited by 65
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
Holze, F., Liechti, M. E., Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Duthaler, U., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2057 · Cited by 65
Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
Mertens, L. J., & Preller, K. H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1341-1907 · Cited by 65
Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use
Walsh, Z., Hendricks, P. S., Smith, S. D., Kosson, D. S., Thiessen, M. S., Lucas, P., & Swogger, M. T. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116642538 · Cited by 67
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine
Malcolm, B., Polanco, M., & Barsuglia, J. P. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1447175 · Cited by 64
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Zeifman, R. J., Singhal, N., Breslow, L., & Weissman, C. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00024 · Cited by 66
Why MDMA therapy for alcohol use disorder? And why now?
Sessa, B. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.004 · Cited by 63
Self-transcendent experience: a grounded theory study
Garcia‐Romeu, A., Himelstein, S., & Kaminker, J. (2014) · Qualitative Research · doi:10.1177/1468794114550679 · Cited by 74
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103149 · Cited by 63
Psychedelic use and intimate partner violence: The role of emotion regulation
Thiessen, M. S., Walsh, Z., Bird, B. M., & Lafrance, A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118771782 · Cited by 60
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Hovmand, O. R., Poulsen, E. D., Arnfred, S., & Storebø, O. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231180276 · Cited by 63
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
Leger, R. F., & Unterwald, E. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211044688 · Cited by 61
Psychedelic pleasures: An affective understanding of the joys of tripping
Bøhling, F. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.07.017 · Cited by 62
Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross‐sectional survey
Perkins, D., Opaleye, E. S., Šimonová, H., Bouso, J. C., Tófoli, L. F., Coelho, N. L. G., Schubert, V., & Sarris, J. J. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13348 · Cited by 54
Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample
Jones, G. M., Ricard, J., Lipson, J., & Nock, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-08085-4 · Cited by 52
Opioid use disorder: current trends and potential treatments
Lee, Y. K., Gold, M. S., Blum, K., Thanos, P. K., Hanna, C., & Fuehrlein, B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1274719 · Cited by 59
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 54
A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience
Gallimore, A. R., & Strassman, R. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00211 · Cited by 56
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 58
Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis.
Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., Rogers, U. A., & Bogenschutz, M. P. (2023) · Psychology of Addictive Behaviors · doi:10.1037/adb0000935 · Cited by 60
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study
van Elk, M., Fejer, G., Lempe, P., Prochazkova, L., Kuchař, M., Hájková, K., & Marschall, J. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05857-0 · Cited by 50
The Effects of Hallucinogens on Gene Expression
Martin, D. A., & Nichols, C. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_479 · Cited by 59
Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002531 · Cited by 54
Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs
Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Lysergic acid diethylamide: a drug of ‘use’?
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316640440 · Cited by 53
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Mitchell, J., & Anderson, B. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01656-7 · Cited by 55
Psilocybin Therapeutic Research: The Present and Future Paradigm
Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00048 · Cited by 49
Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy
Loftis, J. M., & Huckans, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.011 · Cited by 47
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler, E. A. D., Wallace, R. M., Sloshower, J., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 51
Política de drogas e Saúde Coletiva: diálogos necessários
Gomes-Medeiros, D., de Faria, P. H., Campos, G. W. D. S., & Tófoli, L. F. (2019) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00242618 · Cited by 47
Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics
Sexton, J. D., Nichols, C. D., & Hendricks, P. S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00896 · Cited by 46
Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies
Rodrigues, L. S., Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01267-7 · Cited by 47
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Liester, M. B. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120522 · Cited by 45
LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility
Wießner, I., Olivieri, R., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., de Araújo, D. B., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.114 · Cited by 41
Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents
Jaster, A. M., Elder, H., Marsh, S. A., Revenga, M. D. L. F., Negus, S. S., & González‐Maeso, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06092-x · Cited by 45
Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
Jones, G. M., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-06580-2 · Cited by 47
Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
Sakloth, F., Leggett, E., Moerke, M. J., Townsend, E. A., Banks, M. L., & Negus, S. S. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000253 · Cited by 47
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature
Rocha, J. M., Osório, F. D. L., Crippa, J. A. S., Bouso, J. C., Rossi, G. N., Hallak, J. E. C., & SANTOS, R. G. D. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319845774 · Cited by 43
Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD
Lawn, T., Dipasquale, O., Vamvakas, A., Tsougos, I., Mehta, M. A., & Howard, M. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06117-5 · Cited by 39
Medications for treating alcohol use disorder: A narrative review
Kranzler, H. R., & Hartwell, E. E. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15118 · Cited by 50
Negativland - a home for all findings in psychology
Laws, K. R. (2013) · BMC Psychology · doi:10.1186/2050-7283-1-2 · Cited by 45
Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
Morgan, C. J. A., McAndrew, A., Stevens, T., Nutt, D., & Lawn, W. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.10.009 · Cited by 42
Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample
Lafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 42
With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis
Villiger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 43
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
Bedford, P., Hauke, D. J., Wang, Z., Röth, V., Nagy-Huber, M., Holze, F., Ley, L., Vizeli, P., Liechti, M. E., Borgwardt, S., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01574-8 · Cited by 42
Psychedelic treatment of functional neurological disorder: a systematic review
Butler, M., Seynaeve, M., Nicholson, T. R., Pick, S., Kanaan, R., Lees, A. J., Young, A. H., & Rucker, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320912125 · Cited by 39
Effects of 5‐HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self‐administration in male rats
Martin, D. A., Gyawali, U., & Calu, D. J. (2020) · Addiction Biology · doi:10.1111/adb.12926 · Cited by 38
Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice
Alper, K., Cange, J., Sah, R., Schreiber-Gregory, D., Sershen, H. W., & Vinod, K. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1074633 · Cited by 41
LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00994 · Cited by 38
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD)
Halberstadt, A. L., Chatha, M., Klein, A. K., McCorvy, J. D., Meyer, M. R., Wagmann, L., Stratford, A., & Brandt, S. D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107856 · Cited by 38
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Can MDMA Play a Role in the Treatment of Substance Abuse?
Jerome, L., Schuster, S., & Yazar‐Klosinski, B. (2013) · Current Drug Abuse Reviews · doi:10.2174/18744737112059990005 · Cited by 39
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
Argento, E., Braschel, M. C., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 38
The Treatment of Substance Use Disorders: Recent Developments and New Perspectives
Rosenthal, A., Ebrahimi, C., Wedemeyer, F., Romanczuk‐Seiferth, N., & Beck, A. (2022) · Neuropsychobiology · doi:10.1159/000525268 · Cited by 44
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
Kelly, J. R., Clarke, G. A., Harkin, A., Corr, S. C., Galvin, S. D., Pradeep, V., Cryan, J. F., O’Keane, V., & Dinan, T. G. (2022) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2022.100349 · Cited by 40
The History of Psychedelics in Medicine
Sessa, B. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_96-1 · Cited by 44
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Piper, T., Small, F., Brown, S., Kelleher, M., Mitcheson, L., Rucker, J., Young, A. H., & Marsden, J. (2025) · Addiction · doi:10.1111/add.16762 · Cited by 35
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
Johnson, M. W. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_327 · Cited by 37
A Public-Health-Based Vision for the Management and Regulation of Psychedelics
Haden, M., Emerson, B., & Tupper, K. W. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1202459 · Cited by 39
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
Argento, E., Socias, M. E., Hayashi, K., Choi, J., Mackay, L., Christie, D., Milloy, M., & DeBeck, K. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103518 · Cited by 35
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
Prevalence and epidemiological associates of novel psychedelic use in the United States adult population
Sexton, J. D., Crawford, M. S., Sweat, N. W., Varley, A. L., Green, E. E., & Hendricks, P. S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827796 · Cited by 32
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
O’Shaughnessy, D. M., Berlowitz, I., Rodd, R., Sarnyai, Z., & Quirk, F. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320986634 · Cited by 32
LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics
Ruffini, G., Damiani, G., Lozano‐Soldevilla, D., Deco, N., Rosas, F. E., Kiani, N. A., Ponce‐Alvarez, A., Kringelbach, M. L., Carhart-Harris, R. L., & Deco, G. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010811 · Cited by 32
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey
Barnett, B. S., Arakelian, M. H., Beebe, D. S., Ontko, J., Riegal, C., Siu, W. O., Weleff, J., & Pope, H. G. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0036 · Cited by 31
The renaissance in psychedelic research: What do preclinical models have to offer
Murnane, K. S. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.003 · Cited by 35
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
Daldegan‐Bueno, D., Maia, L. O., Massarentti, C. M., & Tófoli, L. F. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06063-2 · Cited by 34
From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide
Smith, D. E., Raswyck, G. E., & Davidson, L. D. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873684 · Cited by 31
Therapist and Patient Perspectives on Ayahuasca-Assisted Treatment for Substance Dependence
Loizaga-Velder, A. K., & Pazzi, A. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_8 · Cited by 31
Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin
Young, S. N. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120128 · Cited by 31
Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology
Tricklebank, M. D., Robbins, T. W., Simmons, C., & Wong, E. H. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05787-x · Cited by 30
Molecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 33
Functional Neuroimaging of Psychedelic Experience: An Overview of Psychological and Neural Effects and their Relevance to Research on Creativity, Daydreaming, and Dreaming
Fox, K. C. R., Girn, M., Parro, C., & Kalina Christoff, A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316556238.007 · Cited by 30

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Harvard University (US)
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2012-03-08
Volume: 26
Issue: 7
Pages: 994-1002
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881112439253
OpenAlex: W1973613743
Cited by: 583
References: 39
Citations by year: 2026: 39 · 2025: 55 · 2024: 67 · 2023: 63 · 2022: 59 · 2021: 52 · 2020: 55 · 2019: 25 · 2018: 34 · 2017: 29 · 2016: 31 · 2015: 25 · 2014: 23 · 2013: 19 · 2012: 6
FWCI: 3.40
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: lysergic acid diethylamide, LSD, alcoholism, alcohol abuse, psychedelic therapy, alcoholism treatment, treatment efficacy
MeSH terms: Adult, Alcoholism, Combined Modality Therapy, Hallucinogens, Humans, Lysergic Acid Diethylamide, Randomized Controlled Trials as Topic, Substance Abuse Treatment Centers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks